Link between Periodontal and Alzheimer’s Disease

A patent application has been filed in the US Patent & Trademark Office (USPTO) entitled, “INHIBITORS OF ARGININE GINGIPAIN”. An Abstract, Background and Summary or Description of said filing follows:


“The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer’s disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.”


“Infection with the bacteria Porphyromonas gingivalis has been linked to the development of periodontal disease, Alzheimer’s and other brain disorders, cardiovascular disease, diabetes, cancer, liver disease, kidney disease, preterm birth, arthritis, pneumonia and other disorders. P. gingivalis is an anaerobic asaccharolytic gram-negative rod bacterium that is known to infect the oral cavity and translocate systemically into coronary arteries, aorta, placental tissue, the brain, the kidneys, and the liver. The bacterium has also been identified in cancerous tissues and a mechanism has been proposed by which gingipains can trigger immortalization and metastasis.”


“In some embodiments, the disease or condition associated with P. gingivalis infection is a brain disorder selected from Alzheimer’s disease, Down’s syndrome, epilepsy, autism, Parkinson’s disease, essential tremor, fronto-temporal dementia, progressive supranuclear palsy, amyotrophic lateral sclerosis, Huntington’s disease, multiple sclerosis, mild cognitive impairment, age associated memory impairment, chronic traumatic encephalopathy, stroke, cerebrovascular disease, Lewy Body disease, multiple system atrophy, schizophrenia, and depression. In some embodiments, the disease or condition associated with P. gingivalis infection is Alzheimer’s disease.”

This application, or a related application, on the above technology is currently pending in the USPTO. Selected portions taken from the file wrapper of the application, including the last action by the patent examiner, last response by applicants attorney and cited art, may be downloaded directly from Patentfox. This presentation and download will provide the reader with an in depth, current, detailed disclosure on advances in this leading edge technology that may not be fully exposed in other published literature.

Copyright © Patentfox, LLC.
All rights reserved in presentation, exclusive of U.S. Government content.

PatentFox Posting No.: 5490
File size:
5.7 MB and about 113 pages.
Download Fee: $25.00 USD. Thank you!

This entry was posted in Biotechnology, Medical Sciences, Pharmaceutical Sciences. Bookmark the permalink.